Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 32.7% in December

Hookipa Pharma Inc (NASDAQ:HOOK) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 30,300 shares, a decline of 32.7% from the November 30th total of 45,000 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 53,000 shares, the days-to-cover ratio is presently 0.6 days.

Hookipa Pharma Trading Up 4.9 %

HOOK stock traded up $0.09 during trading on Friday, reaching $1.94. 144,427 shares of the stock were exchanged, compared to its average volume of 59,105. The firm’s 50 day moving average is $2.86 and its 200 day moving average is $4.48. The firm has a market cap of $23.39 million, a P/E ratio of -0.52 and a beta of 0.71. Hookipa Pharma has a twelve month low of $1.75 and a twelve month high of $10.50.

Hedge Funds Weigh In On Hookipa Pharma

A number of institutional investors have recently modified their holdings of HOOK. Acadian Asset Management LLC grew its position in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after buying an additional 83,800 shares in the last quarter. Finally, Ikarian Capital LLC acquired a new position in shares of Hookipa Pharma during the third quarter valued at about $228,000. 63.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOOK has been the subject of a number of research analyst reports. JMP Securities lowered their target price on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Royal Bank of Canada downgraded shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $48.00 to $2.00 in a research report on Friday, December 20th.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.